ALPINE IMMUNE SCIENCES, INC. - FORM S-1 - EX-23.2 - May 13, 2015

Attached files

file filename
S-1 - S-1 - ALPINE IMMUNE SCIENCES, INC.a2224618zs-1.htm
EX-4.3 - EX-4.3 - ALPINE IMMUNE SCIENCES, INC.a2224618zex-4_3.htm
EX-3.2 - EX-3.2 - ALPINE IMMUNE SCIENCES, INC.a2224618zex-3_2.htm
EX-4.1 - EX-4.1 - ALPINE IMMUNE SCIENCES, INC.a2224618zex-4_1.htm
EX-4.2 - EX-4.2 - ALPINE IMMUNE SCIENCES, INC.a2224618zex-4_2.htm
EX-3.3 - EX-3.3 - ALPINE IMMUNE SCIENCES, INC.a2224618zex-3_3.htm
EX-4.4 - EX-4.4 - ALPINE IMMUNE SCIENCES, INC.a2224618zex-4_4.htm
EX-3.1 - EX-3.1 - ALPINE IMMUNE SCIENCES, INC.a2224618zex-3_1.htm
EX-3.5 - EX-3.5 - ALPINE IMMUNE SCIENCES, INC.a2224618zex-3_5.htm
EX-3.4 - EX-3.4 - ALPINE IMMUNE SCIENCES, INC.a2224618zex-3_4.htm
EX-10.5 - EX-10.5 - ALPINE IMMUNE SCIENCES, INC.a2224618zex-10_5.htm
EX-10.1 - EX-10.1 - ALPINE IMMUNE SCIENCES, INC.a2224618zex-10_1.htm
EX-10.6 - EX-10.6 - ALPINE IMMUNE SCIENCES, INC.a2224618zex-10_6.htm
EX-10.7 - EX-10.7 - ALPINE IMMUNE SCIENCES, INC.a2224618zex-10_7.htm
EX-10.4 - EX-10.4 - ALPINE IMMUNE SCIENCES, INC.a2224618zex-10_4.htm
EX-10.9 - EX-10.9 - ALPINE IMMUNE SCIENCES, INC.a2224618zex-10_9.htm
EX-10.2 - EX-10.2 - ALPINE IMMUNE SCIENCES, INC.a2224618zex-10_2.htm
EX-10.3 - EX-10.3 - ALPINE IMMUNE SCIENCES, INC.a2224618zex-10_3.htm
EX-10.8 - EX-10.8 - ALPINE IMMUNE SCIENCES, INC.a2224618zex-10_8.htm
EX-10.13 - EX-10.13 - ALPINE IMMUNE SCIENCES, INC.a2224618zex-10_13.htm
EX-10.16 - EX-10.16 - ALPINE IMMUNE SCIENCES, INC.a2224618zex-10_16.htm
EX-10.11 - EX-10.11 - ALPINE IMMUNE SCIENCES, INC.a2224618zex-10_11.htm
EX-10.17 - EX-10.17 - ALPINE IMMUNE SCIENCES, INC.a2224618zex-10_17.htm
EX-10.10 - EX-10.10 - ALPINE IMMUNE SCIENCES, INC.a2224618zex-10_10.htm
EX-10.15 - EX-10.15 - ALPINE IMMUNE SCIENCES, INC.a2224618zex-10_15.htm
EX-10.18 - EX-10.18 - ALPINE IMMUNE SCIENCES, INC.a2224618zex-10_18.htm
EX-10.12 - EX-10.12 - ALPINE IMMUNE SCIENCES, INC.a2224618zex-10_12.htm
EX-10.14 - EX-10.14 - ALPINE IMMUNE SCIENCES, INC.a2224618zex-10_14.htm

Exhibit 23.2

 

Consent of Independent Registered Public Accounting Firm

 

We consent to the reference to our firm under the caption “Experts” and to the use of our report dated March 17, 2015, in the Registration Statement (Form S-1) and related Prospectus of Nivalis Therapeutics, Inc.  for the registration of shares of its common stock.

 

 

 

/s/ Ernst & Young LLP

 

Denver, Colorado
May 13, 2015

 


ALPINE IMMUNE SCIENCES, INC. Reports

Also read